Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States

Gastroenterology

Volumn 124, Issue 7, 2003, Pages 1821-1829

  Ruhl, Constance E ^a   Everhart, James E ^b  

^a SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA CAROTENE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CRYPTOXANTHIN; IRON; MINERAL; SELENIUM; TRANSFERRIN; VITAMIN; XANTHOPHYLL; ZEAXANTHIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; IRON BLOOD LEVEL; LIVER INJURY; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

EID: 0038281500     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00395-0     Document Type: Article

References (43)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
3. Reid AE. Nonalcoholic steatolhepatitis. Gastroenterology 2001;121:710-723.
4. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-774.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
6. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-262.
7. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
8. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
10. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-1163.
11. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429.
12. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939.
13. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-738.
14. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672.
15. Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML, Mills S. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis (abstr). Hepatology 2002;96:382A.
16. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000;136:727-733.
17. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. Can J Gastroenterol 2000;14:321-326.
18. Laurin J. Motionn - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 2002;16:722-726.
19. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. National Center for Health Statistics. Vital Health Stat Series 1, No. 32. 1994;1-34.
20. U.S. Department of Health and Human Services (DHHS), National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, reference manuals and reports: manual for medical technicians and laboratory procedures used for NHANES III (CD-ROM). National Health and Nutrition Examination Survey III, 1988-94 (NCHS CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
21. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, Grummer-Strawn LM, Sampson EJ, Khoury MJ, Gallagher ML. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-2222.
22. National Center for Health Statistics. NHANES III DNA Specimens Guidelines for Proposals. Federal Register Vol. 67 no. 153 2002: 51585-51589. Available: www.cdc.gov/nchs/about/major/nhanes/dnafnlgm2.htm. Accessed August 8, 2002.
23. National Health and Nutrition Examination Survey III; Body measurements (anthropometry). Rockville, MD: Westat, 1988.
24. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
25. Research Triangle Institute. SUDAN user's manual release 7.0. Research Triangle Park, NC: Research Triangle Institute, April, 1996.
26. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
27. Daniel S, Ben Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014.
28. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
29. Brittenham GM. Disorders of iron metabolism: iron deficiency and overload, In: Hoffman R, Benz J, Shattil SJ, Furie B, Cohen HJ, Silberstien LE, McGlave P, eds. Hematology: basic principles and practice (3rd ed). Philadelphia: Churchill Livingstone, 2000:397-428.
30. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850.
31. Ioannou GN, Tung BY, Kowdley KV. Iron in hepatitis C: villain or innocent bystander? Semin Gastrointest Dis 2002;13:95-108.
32. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001;33:157-162.
33. Desai TK, Chiorean M. Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis (abstr). Gastroenterology 1998;114:A1233.
34. Nitecki J, Jackson FW, Allen ML, Farr VL, Jackson FW. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) (abstr). Gastroenterology 2000;118:A1474.
35. Agrawal S, Bonkovsky HL. Management of nonalcoholic steatohepatitis: an analytic review. J Clin Gastroenterol 2002;35:253-261.
36. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75:733-739.
37. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical - mediated process? Hepatology 1990;11:127-137.
38. Bacon BR, O'Neill R, Britton RS. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993;105:1134-1140.
39. Pietrangelo A, Gualdi R, Casalgrandi G, Geerts A, De Bleser P, Montosi G, Ventura E. Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hepatology 1994;19:714-721.
40. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
41. Guillygomarc'h A, Mendler MH, Moirand R, Laine F, Quentin V, David V, Brissot P, Deugnier Y. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001;35:344-349.
42. Shils ME, Olson JA, Shike M, Ross AC. Modern nutrition in health and disease (9th ed). Philadelphia: Lippincott Williams & Wilkins, 1999.
43. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702-1704.